Cargando…

Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup

Introduction. (18)F-FDG-PET-CT plays an important role in the management of lymphoma postchemotherapy followup. Some centres perform prechemotherapy baseline CT and postchemotherapy PETCT. With a concern of radiation burden, especially in young patients, this study aimed to assess if PETCT radiation...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonoda, L. I., Sanghera, B., Wong, W. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific World Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324157/
https://www.ncbi.nlm.nih.gov/pubmed/22545010
http://dx.doi.org/10.1100/2012/208135
_version_ 1782229286662438912
author Sonoda, L. I.
Sanghera, B.
Wong, W. L.
author_facet Sonoda, L. I.
Sanghera, B.
Wong, W. L.
author_sort Sonoda, L. I.
collection PubMed
description Introduction. (18)F-FDG-PET-CT plays an important role in the management of lymphoma postchemotherapy followup. Some centres perform prechemotherapy baseline CT and postchemotherapy PETCT. With a concern of radiation burden, especially in young patients, this study aimed to assess if PETCT radiation dose could be reduced. Methods. Retrospective analysis of 100 lymphoma patients was performed to record sites of disease on prechemotherapy CT and postchemotherapy PETCT. The potential reduction in radiation and time achieved with PETCT limited to sites of known disease identified on prechemotherapy CT was calculated. Results. No FDG-uptake was seen in 72 cases. FDG uptake at known disease sites was seen in 24. Of the remaining 4, one had clinically significant pathology, a rectal adenocarcinoma. PETCT did not reveal any unexpected sites of lymphoma. Limiting PETCT to sites of known disease would have saved a mean radiation dose of 4 mSv (27.3%), with a mean time of 16 minutes. Conclusion. Our study suggests that young patients may benefit from reduced radiation by limiting PETCT to sites of known disease with low risk of missing significant pathology. However, in older patients, with increased incidence of asymptomatic synchronous malignancies, whole-body PETCT is advisable unless prechemotherapy PETCT has been performed.
format Online
Article
Text
id pubmed-3324157
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The Scientific World Journal
record_format MEDLINE/PubMed
spelling pubmed-33241572012-04-27 Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup Sonoda, L. I. Sanghera, B. Wong, W. L. ScientificWorldJournal Clinical Study Introduction. (18)F-FDG-PET-CT plays an important role in the management of lymphoma postchemotherapy followup. Some centres perform prechemotherapy baseline CT and postchemotherapy PETCT. With a concern of radiation burden, especially in young patients, this study aimed to assess if PETCT radiation dose could be reduced. Methods. Retrospective analysis of 100 lymphoma patients was performed to record sites of disease on prechemotherapy CT and postchemotherapy PETCT. The potential reduction in radiation and time achieved with PETCT limited to sites of known disease identified on prechemotherapy CT was calculated. Results. No FDG-uptake was seen in 72 cases. FDG uptake at known disease sites was seen in 24. Of the remaining 4, one had clinically significant pathology, a rectal adenocarcinoma. PETCT did not reveal any unexpected sites of lymphoma. Limiting PETCT to sites of known disease would have saved a mean radiation dose of 4 mSv (27.3%), with a mean time of 16 minutes. Conclusion. Our study suggests that young patients may benefit from reduced radiation by limiting PETCT to sites of known disease with low risk of missing significant pathology. However, in older patients, with increased incidence of asymptomatic synchronous malignancies, whole-body PETCT is advisable unless prechemotherapy PETCT has been performed. The Scientific World Journal 2012-04-01 /pmc/articles/PMC3324157/ /pubmed/22545010 http://dx.doi.org/10.1100/2012/208135 Text en Copyright © 2012 L. I. Sonoda et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Sonoda, L. I.
Sanghera, B.
Wong, W. L.
Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
title Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
title_full Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
title_fullStr Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
title_full_unstemmed Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
title_short Investigation of Dose Minimisation Protocol for (18)F-FDG PET-CT in the Management of Lymphoma Postchemotherapy Followup
title_sort investigation of dose minimisation protocol for (18)f-fdg pet-ct in the management of lymphoma postchemotherapy followup
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324157/
https://www.ncbi.nlm.nih.gov/pubmed/22545010
http://dx.doi.org/10.1100/2012/208135
work_keys_str_mv AT sonodali investigationofdoseminimisationprotocolfor18ffdgpetctinthemanagementoflymphomapostchemotherapyfollowup
AT sangherab investigationofdoseminimisationprotocolfor18ffdgpetctinthemanagementoflymphomapostchemotherapyfollowup
AT wongwl investigationofdoseminimisationprotocolfor18ffdgpetctinthemanagementoflymphomapostchemotherapyfollowup